EU approves AstraZeneca’s drug for adjunct use in Type-1 diabetes
(Reuters) – British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease.
Forxiga can now be used along with insulin in patients with Type-1 diabetes and a Body Mass Index (BMI) of 27 or more when insulin alone has not been able to control blood sugar levels, the company said https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-europe-for-type-1-diabetes22032019.html. Type-1 diabetes is a chronic condition in which the pancreas produces little or no insulin hormone.
More here –> Euronews.com